If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 41 - 50 of 293
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Atezolizumab in Patients with Advanced Cancers Associated with Expression of Delta-l
Phase 1/2 open-label, multicenter study to evaluate the safety, PK, and pharmacodynamics of HPN328 in patients with SCLC or with advanced solid tumors associated with expression of DLL3. This study will be divided into 2 parts: Dose Escalation (Part 1) and Expansion (Part 2).
Protocol No
HARPOON-HPN328-4001
Categories
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Protocol No
NRG-GY026
Categories
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3 and 4-1BB Signaling Domains in Patients with Relapsed and/or Refractory CD19 or CD20 B-Cell Acute Lymphoblastic Leukemia
Phase 1 Study of CAR-20/19-T Cells in Pediatric and Young adult Patients with R/R B Cell ALL
Protocol No
IIT-TALANO-CART-ALL
Categories
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 as Monotherapy or in Combination with Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
Protocol No
ADP-0055-001-MAGE-A4-SURPASS
Categories
Cancer,
Colorectal,
Skin Cancers,
Thoracic Cancers,
Sarcoma,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Other Respiratory,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Ovary,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
A Phase 1b/2 Study of BGB-11417 in Patients with Myeloid Malignancies
Protocol No
BEIGENE-BGB-11417-103
Categories
A Study to Assess Video Hand Opening Time and Ambulation in Healthy Volunteers and Individuals with Myotonic Dystrophy Type 1
A Study to Evaluate Video Hand Opening Time and Ambulation
Protocol No
NEURO-VERTEX-VX22-MDO-801
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol No
NRG-GU012-SAMURAI
Categories
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma
This is a Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Protocol No
VMONCOLOGY-VMO-01C
Evaluation of the GORE VIAFORT Vascular Stent for Treatment of Symptomatic Iliofemoral Venous Obstruction
GORE VIAFORT Vascular Stent Iliofemoral Study
Protocol No
VIR-WLGORE-VIAFORT
Categories
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Infusion of Danavorexton in Participants With Moderate to Severe Obstructive Sleep
Intravenous Danavorexton v Placebo in Moderate to Severe Sleep Apnea
Protocol No
ANES-TAKEDA-TAK-925-1501
Categories